Regenerative Medicine Market in Japan Size to grow by USD 2328.47 million between 2023-2027

According to a research report “ Regenerative Medicine Market in Japan” by Application (Oncology, Musculoskeletal, Dermatology, Immunology and Inflammation and others) Technology (Cell, tissue-based, Gene therapy) Geography (Asia)- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 2328.47 million, at a CAGR of  15.89% during the forecast period. In the dynamic landscape of the Japanese market, regenerative medicine, spearheaded by stem cell technology, is gaining significant traction. Stem cells, with their multifaceted applications in areas such as tissue engineering, cellular therapies, and gene therapy, offer the potential to replace damaged cells and tissues in various health conditions, including spinal cord injuries, arthritis, and Parkinson's disease. The increasing adoption rate of stem cell technologies in disease treatment is fueled by advancements in stem cell-based therapies, particularly in the realm of nanotechnology, which is increasingly being utilized for stem cell engineering and regenerative medicine applications. These technological innovations are revolutionizing the perspective of researchers on regenerative medicines and are a key catalyst for their development in Japan.

Browse market data tables, figures, and in-depth TOC on “Regenerative Medicine Market in Japan” by Application (Oncology, Musculoskeletal, Dermatology, Immunology and Inflammation and others) Technology (Cell, tissue-based, Gene therapy) Geography (Asia) Global Forecast to 2027. Download Free Sample

By Application, the Oncology segment is projected to dominate the market size in 2024

In the realm of Regenerative Medicine, cell therapy and tissue engineering are two pivotal technologies driving innovation. Cell therapy involves the administration of living cells, such as somatic cells and stem cells including embryonic stem cells, progenitor cells, hematopoietic stem cells, and mesenchymal stem cells, into an individual's body to restore organ function. Tissue engineering, an interdisciplinary field, combines life sciences and engineering principles. It produces tissue-engineered products, which consist of cells and biologically active molecules, to enhance or replace damaged biological tissues. These products may contain human, animal, or both viable and non-viable cells or tissues.

By Technology, Cell  segment is expected to hold the largest market size for the year 2024

In the Japanese healthcare sector, regenerative medicine is gaining significant traction, particularly in the field of oncology. These advanced therapies enhance the patient's immune system's capacity to combat cancer cells. The process involves extracting a specific cell set from a patient's blood, engineering them to become more potent against cancer cells, and subsequently reintroducing them back into the patient's body. Notable applications include the treatment of blood-related diseases such as non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and leukemia. Rituximab (Rituxan) and lenalidomide (Revlimid) are approved drugs used for lymphomas and leukemias, respectively, while stem cell transplants may involve removing cancer cells from the transplanted stem cells or transplant patients.

Asia is forecasted to hold the largest market size by region in 2024

ai_geographic_landscape

The Regenerative Medicine Market in Japan growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

• Astellas Pharma Inc.
• Becton Dickinson and Co.
• CellSeed Inc.
• Cellusion Inc.
• Cyfuse Biomedical K.K.
• F. Hoffmann La Roche Ltd.
• FUJIFILM Corp.
• HEALIOS K.K.
• iHeart Japan Corp.
• Japan Tissue Engineering Co. Ltd.
• JCR Pharmaceticals Co. Ltd.
• MEDINET Co. Ltd.
• Metcela Inc.
• Nikon Corp.
• ROHTO Pharmaceutical Co. Ltd.
• Sumitomo Pharma Co. Ltd.
• Takara Bio Inc.
• Takeda Pharmaceutical Co. Ltd.
• Terumo Corp.
• Yokogawa Electric Corp.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Regenerative medicine, a rapidly growing field in Japan's healthcare sector, utilizes advanced biotechnology and pharmaceuticals to develop therapies for various diseases. The Japanese government and regulatory bodies have been supportive of this innovation, with clear regulatory pathways and approvals for stem cell research and therapies. Doctors and hospitals are increasingly adopting regenerative medicine for the treatment of diseases such as Cardiovascular, Musculoskeletal, Dermatology, and neurological conditions. Patients in Japan, particularly the aging population and geriatric patients, stand to benefit significantly from these therapies. The Japanese government has been investing heavily in regenerative medicine, recognizing its potential to drive growth in the healthcare sector. Clinical trials for gene therapies, cell therapy, and cell-based immunotherapy are underway, with promising results. However, ethical issues surrounding the use of embryonic stem cells and ethical considerations remain a concern. The regulatory framework for regenerative medicine in Japan is continually evolving to address these concerns. With continued investment, innovation, and research, regenerative medicine is poised to revolutionize the healthcare industry in Japan. The healthcare expenditure on regenerative medicine is expected to grow significantly in the coming years, making it a key area of focus for stakeholders in the healthcare ecosystem.

Market Research Overview

ai_research_analyst_overview

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/